STAAR SURGICAL COMPANY

(STAA)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
111.58 USD   +9.36%
08/11STAAR SURGICAL : Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development - Form 8-K
PU
08/11STAAR SURGICAL CO : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/11SECTOR UPDATE : Health Care Stocks on Downward Slide
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
87.72(c) 82.89(c) 87.44(c) 102.03(c) 111.58(c) Last
429 453 376 958 517 693 1 872 586 826 953 Volume
+3.80% -5.51% +5.49% +16.69% +9.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 295 M - -
Net income 2022 33,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 162x
Yield 2022 -
Sales 2023 375 M - -
Net income 2023 53,6 M - -
Net Debt 2023 - - -
P/E ratio 2023 101x
Yield 2023 -
Capitalization 5 360 M 5 360 M -
Capi. / Sales 2022 18,2x
Capi. / Sales 2023 14,3x
Nbr of Employees 697
Free-Float 99,3%
More Financials
Company
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom and Singapore, with a... 
More about the company
Ratings of STAAR Surgical Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about STAAR SURGICAL COMPANY
08/11STAAR SURGICAL : Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Co..
PU
08/11STAAR SURGICAL CO : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/11SECTOR UPDATE : Health Care Stocks on Downward Slide
MT
08/11STAAR Surgical Q2 Results Rise; Shares Jump Thursday
MT
08/11SECTOR UPDATE : Health Care Stocks Struggling for Direction
MT
08/11Jefferies Adjusts STAAR Surgical's Price Target to $125 From $165; Buy Rating Kept
MT
08/11Canaccord Genuity Adjusts Price Target on STAAR Surgical to $97 From $89, Reiterates Bu..
MT
08/11BTIG Adjusts STAAR Surgical's Price Target to $103 From $98, Reiterates Buy Rating
MT
08/11Benchmark Adjusts STAAR Surgical's Price Target to $117 From $97, Reiterates Buy Rating
MT
08/11Needham Raises STAAR Surgical's Price Target to $110 From $87, Reiterates Buy Rating
MT
08/10STAAR SURGICAL : Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y - For..
PU
08/10STAAR SURGICAL : Q2 Earnings Snapshot
AQ
08/10TRANSCRIPT : STAAR Surgical Company, Q2 2022 Earnings Call, Aug 10, 2022
CI
08/10STAAR SURGICAL CO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
08/10STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions..
BU
More news
News in other languages on STAAR SURGICAL COMPANY
08/11MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en baisse
08/11STAAR SURGICAL : BPA ajusté et recettes en hausse au 2e trimestre
08/11MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en quête de direction
08/10Earnings Flash (STAA) STAAR SURGICAL COMPANY affiche un chiffre d'affaires de 81,1 mill..
08/10STAAR Surgical Company réaffirme ses prévisions de ventes pour l'année 2022
More news
Analyst Recommendations on STAAR SURGICAL COMPANY
More recommendations
Chart STAAR SURGICAL COMPANY
Duration : Period :
STAAR Surgical Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STAAR SURGICAL COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 111,58 $
Average target price 108,50 $
Spread / Average Target -2,76%
EPS Revisions
Managers and Directors
Caren L. Mason Director
Patrick F. Williams Chief Financial Officer & Vice President
Thomas G. Frinzi Chairman
Keith Holliday Chief Technology Officer
Scott D. Barnes Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
STAAR SURGICAL COMPANY22.21%5 360
ABBOTT LABORATORIES-20.79%195 226
MEDTRONIC PLC-8.34%125 988
BECTON, DICKINSON AND COMPANY7.29%75 203
HOYA CORPORATION-14.17%39 624
SARTORIUS STEDIM BIOTECH-20.96%36 037